ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Kala Pharmaceuticals Receives FDA Complete Response Letter for KPI-121 0.25% NDA and Plans to Respond with Data From STRIDE 3 Trial
August 15, 2019Kala Pharmaceuticals, Inc. announced that it received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s new drug application (NDA) for... -
Kala Receives CRL from FDA for KPI-121 0.25% NDA for Dry Eye Disease
August 12, 2019Kala Pharmaceuticals has received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s new drug application (NDA) for KPI-121 0.25% for the temporary relief of the signs and symptoms of dry eye disease.
Pharma Sources Insight January 2025
